In Brief This Week: Roche; Danaher; Transgenomic; and More | GenomeWeb

NEW YORK (GenomeWeb) — Roche has received regulatory clearance to finalize its acquisition of Kapa Biosystems, the company announced this week. Wilmington, Massachusetts-based Kapa develops genomics tools. Its acquisition will add to Roche's NGS portfolio by building on its existing NGS target enrichment products, Roche said. Terms of the deal were undisclosed.


Danaher announced this week that its board of directors has approved a quarterly share dividend of $.135 per share, which will be paid on Jan. 29, 2016 to holders of record on Dec. 21, 2015.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.